Integra LifeSciences completed the acquisition of Acclarent from Ethicon and Johnson & Johnson for $280m.

Integra LifeSciences, a global medical device manufacturing company, completed the acquisition of Acclarent, a developer of technology for ENT related illnesses, from Ethicon, a manufacturer of surgical sutures and wound closure devices, and Johnson & Johnson, a pharmaceutical company, for $280m. “This acquisition presents Integra with a rare opportunity to become a key player in the ENT segment. Acclarent’s culture of pioneering technologies aligns with Integra’s legacy of innovation to transform care and restore patients’ lives. We are looking forward to welcoming the Acclarent employees to the Integra team. Together, we can make a profound impact on the future of ENT and neurosurgery,” Jan De Witte, Integra LifeSciences President and CEO.